A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
Joseph Kim,Navid Hafez,Hatem Soliman,Siqing Fu,Shumei Kato,P. N. Lara,Ulka N. Vaishampayan,Albiruni Ryan Abdul Razak,Dana Backlund Cardin,Pamela N. Munster,Joseph Paul Eder,Elizabeth M. Swisher,Andrew B. Nixon,Abhijit A. Patel,Yu Shyr,S. Percy Ivy,Patricia LoRusso +16 more
TL;DR: Cediranib suppresses expression of BRCA1, BRCa2, and RAD51 and increases sensitivity of tumors to poly-...
Proceedings ArticleDOI
Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
Ping Chi,Filip Janku,Michael Heinrich,Kristen N. Ganjoo,Hans Gelderblom,Michael S. Gordon,Robin L. Jones,Albiruni Ryan Abdul Razak,Jonathan C. Trent,Margaret von Mehren,Simin Hu,Ying Su,Rodrigo Ruiz-Soto,Suzanne George +13 more
TL;DR: This abstract reports updated results from the escalation and expansion phases of the Phase 1 study for pts treated with ≥100 mg daily ripretinib, a kinase switch control inhibitor designed to broadly inhibit KIT and PDGFRA mutations.
Journal ArticleDOI
Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Aaron R. Hansen,K. Ala-leppilampi,Chris McKillop,L.L. Siu,P. Bedard,Albiruni Ryan Abdul Razak,A. Spreafico,Srikala S. Sridhar,Natasha B. Leighl,M.O. Butler,David W. Hogg,Adrian G. Sacher,Amit M. Oza,Rosane Nisenbaum,Kimberly Webster,David Cella,Janet A. Parsons +16 more
TL;DR: This 25 item list is the first HRQOL toxicity subscale developed with patient and clinician input for patients treated with ICMs and will be combined with the FACT-ICM and this PRO instrument will undergo further validity testing.
Journal ArticleDOI
A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors
Albiruni Ryan Abdul Razak,Lia Gore,Carolyn D. Britten,Wilson H. Miller,G.L. Uy,G. Nichols,S.A. Middleton,S. Blotner,J. Zhi,Lori Jukofsky,William E. Pierceall,Brian Higgins,L.C. Chen +12 more
Journal ArticleDOI
SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
Dejka M. Araujo,Mihaela Druta,Mark Agulnik,Sandra P. D'Angelo,Jean-Yves Blay,Sandra J. Strauss,Claudia Valverde,Albiruni Ryan Abdul Razak,Erin Van Winkle,Trupti Trivedi,Swethajit Biswas,Dennis Williams,Elliot Norry +12 more
TL;DR: ADP-A2M4 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered to target MAGE-A4+ tumors in the context of HLA-A*02.